Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hidradenitis Suppurativa (HS): early-phase trial registry
10 of 13 indexed Hidradenitis Suppurativa (HS) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 10 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Hidradenitis Suppurativa (HS): 13 US clinical trials tracked, 10 recruiting.
Hidradenitis Suppurativa (HS) is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Incyte Corporation, running 3 of these trials.
Enrollment posture brief
Registry condition hidradenitis-suppurativa-hs
OPEN 10 | RECR 77% | LATE 3 | EARLY 8 | RANK #1315 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Firearm Injury (77% recruiting · 13 trials)
Hidradenitis Suppurativa (HS) lists 10 open slots (77% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hidradenitis Suppurativa (HS) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hidradenitis Suppurativa (HS) is recruiting above its size-band peers.
10 of 13 indexed trials (76.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Hidradenitis Suppurativa (HS) research.
Incyte Corporation accounts for 3 of 13 trials (23.1%). 11 distinct sponsors appear on at least one study for this condition label.
-
Typical Hidradenitis Suppurativa (HS) enrolment sits around 40 participants.
Median target enrolment is 40 among the 13 trials that report a genuine target (sentinel values excluded). 7 of those (53.8%) plan for fewer than 100 participants.
-
Hidradenitis Suppurativa (HS) research is mostly interventional.
12 interventional and 1 observational studies make up this index (92.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Incyte Corporation
NCT06855498
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
Zura Bio
NCT06993610
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
Bluefin Biomedicine
NCT07287644
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
Navigator Medicines
NCT07384975
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Incyte Corporation
NCT07213973
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
Sonoma Biotherapeutics
NCT07123038
1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)
Wynn Medical Center
NCT07155239
The Safety and Efficacy of Roflumilast Foam in HS
Beth Israel Deaconess Medical Center
NCT07263230
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
Virginia Clinical Research
NCT06645821
Pelashield™ PainGuard™ vs Restrata® in HS Surgery
Rutgers, The State University of New Jersey
NCT07316192
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Incyte Corporation
NCT06212999
Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically
AbbVie
NCT02808975
Hidradenitis Suppurativa Wound Care
Wake Forest University Health Sciences
NCT04354012
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 6 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Hidradenitis Suppurativa (HS) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hidradenitis Suppurativa (HS) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hidradenitis Suppurativa (HS) page
13 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Hidradenitis Suppurativa (HS) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Incyte Corporation sponsors the most Hidradenitis Suppurativa (HS) trials on record, review their full trial history before evaluating a specific study. See Incyte Corporation's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hidradenitis Suppurativa (HS) condition card totals 13 registered trials; most-linked intervention Povorcitinib; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.